PHARMA CONSULT
ActivePHARMA CONSULT has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €262k and a net result of €79k. Equity is growing by ~26.3% per year across the filed fiscal years. Its solvency ranks better than 66% of 8967 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 1.5% (low).
Checked score
Score 2024
72
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability95▲+18
Solvency95▼-1
Growth52=
Track record94
Bankruptcy probability, 12 months
1.5%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €18k at 30 days acceptable
Liquidity ample (current ratio 3.36 against 3.39 in 2023; short-term debt: 29.6% and cash: 6.7% of total assets), and 29.6% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Four signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 15-09-2025, 46 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 3 filingsDeviation from the deadline
2025
not confirmed
2024
46 d late
2023
89 d late
2022
353 d late
← before the deadline
after the deadline →
Financials · fiscal year 2024, micro schema
Turnover
€304k
EBIT margin
70.0%
Net result
€79k▲ 373%
2023 · €17k
2022: €163k
2023: €17k
2022 → 2024
Working capital
€259k▲ 43.4%
2023 · €181k
2022: €166k
2023: €181k
2022 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line202220232024Trend
Turnover€304k-
Equity€166k-€182k▲ 10.1%€262k▲ 43.4%
Operating result€213k-€23k▼ 89.2%€102k▲ 346%
Net result€163k-€17k▼ 89.7%€79k▲ 373%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2024; 2024 is 346% above 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €371k
Fixed assets
€3k▲ 41.7%
Current assets
€369k▲ 43.9%
Equity and liabilities €371k
Equity
€262k▲ 43.4%
Debt
€110k▲ 45.0%
The debt ratio rises from 29.3% to 29.6%. Equity and debt are higher.
Key figures and ratios
EBITDA
€103k▲
2023 · €23k
Cash flow
€79k▲
2023 · €17k
Solvency
70.4%▼
2023 · 70.7%
Current ratio
3.36▼
2023 · 3.39
Quick ratio
3.36▼
2023 · 3.39
Debt / equity
0.42▲
2023 · 0.42
ROE
30.3%▲
2023 · 9.2%
ROA
21.3%▲
2023 · 6.5%
Interest coverage
176.54▼
2023 · 278.05
Debt
€110k▲
2023 · €76k
Debt ≤ 1 year
€110k▲
2023 · €76k
Income taxes
€23k▲
2023 · €6k
Staff costs
€671▼
2023 · €2k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2024 against 2023
Balance sheet
Code20232024
Assets
Total assets20/58€258k€371k▲
Fixed assets21/28€2k€3k▲
Tangible fixed assets22/27€2k€3k▲
Plant, machinery and equipment23€2k€3k▲
Current assets29/58€256k€369k▲
Amounts receivable within one year40/41€219k€342k▲
Trade receivables40€142k€171k▲
Other amounts receivable41€77k€171k▲
Cash at bank and in hand54/58€36k€25k▼
Deferred charges and accrued income490/1€1k€1k▼
Equity and liabilities
Total equity and liabilities10/49€258k€371k▲
Equity10/15€182k€262k▲
Contributions10/11€3k€3k=
Profit (loss) carried forward14€180k€259k▲
Amounts payable17/49€76k€110k▲
Amounts payable within one year42/48€76k€110k▲
Trade debts44€3k€766▼
Suppliers440/4€3k€766▼
Taxes, remuneration and social security45€73k€109k▲
Taxes450/3€65k€105k▲
Remuneration and social security454/9€8k€4k▼
Income statement
Code20232024
Remuneration, social security and pensions62€2k€671▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€93€230▲
Other operating charges640/8€606€1k▲
Non-recurring operating charges66A€50k-
Gross operating margin9900€75k€105k▲
Operating profit (loss)9901€23k€102k▲
Financial income75/76B-€4
Recurring financial income75-€4
Financial charges65/66B€83€581▲
Recurring financial charges65€83€581▲
Profit (loss) for the period before taxes9903€23k€102k▲
Income taxes67/77€6k€23k▲
Profit (loss) for the period9904€17k€79k▲
Profit (loss) for the period to be appropriated9905€17k€79k▲
Appropriation of the result
Profit (loss) to be appropriated9906€180k€259k▲
Profit (loss) brought forward from the previous period14P€163k€180k▲
The notes to these accounts (7 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
15-09
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 46 days late
2024
31-12
Financial
Equity above €200kEq €262k ▲43.4%
3 profitable years in a row build equity to €262k.
28-10
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 89 days late
18-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 353 days late
2023
31-12
Financial
Weakest financial yearnet €17k ▼89.7%
Net result drops to €17k, the lowest in the series; recovery starts the following year.
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Brugelette · 1 establishment unit since 2022
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Chasse Royale(A) 1bis7941 BrugeletteGround area
3,535 m²
Building footprint
967 m²
Volume, LiDAR
7,766 m³
Parcel 51005B0152/00K000, Wallonia · tallest building 12.0 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
PHARMA CONSULT
since 20222.328.497.866
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 51005B0152/00K000 | Wallonia | 3,535 m² | 1 · 967 m² | 12.0 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Secur'mm
BE 0671.792.603
Sint-Truiden · Eq €262k
Weckx Consulting
BE 0778.870.804
Bekkevoort · Eq €262k
KAB
BE 0839.137.496
Büllingen · Eq €262k
de Gooijer Consulting
BE 0787.576.949
Kraainem · Eq €261k
DIEDERT DEBUSSCHER
BE 0889.537.411
Oosterzele · Eq €261k
Of 13,422 companies in sector 73300 we hold annual accounts for 6,900. 4,977 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded22-02-2022
Fiscal year end31-12
Activities, NACEBEL
70210Activities of head offices; management consultancy activities
73300Public relations and communication consultancy
74909Other professional, scientific and technical activities
74999Other professional, scientific and technical activities
Sources
Crossroads Bank for EnterprisesNational Bank · 3 filingsAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
1 entryE-mail:jm.rasse@pharmaconsult.be